168 related articles for article (PubMed ID: 17484924)
1. The challenge of poor-prognosis germ cell tumors.
Toner GC
Urol Clin North Am; 2007 May; 34(2):187-97; abstract ix. PubMed ID: 17484924
[TBL] [Abstract][Full Text] [Related]
2. Poor prognosis germ-cell tumors: An unresolved challenge.
Toner GC; Frydenberg M
Semin Urol Oncol; 2002 Nov; 20(4):251-61. PubMed ID: 12489058
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced germ cell tumors.
Kondagunta GV; Motzer RJ
J Clin Oncol; 2006 Dec; 24(35):5493-502. PubMed ID: 17158534
[TBL] [Abstract][Full Text] [Related]
4. [Germ cell tumors of the testes: state of the art].
Fléchon A; Droz JP
Cancer Radiother; 2000; 4(1):27-31. PubMed ID: 10742806
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
6. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
7. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
8. Management of advanced germ-cell tumors of the testis.
Fléchon A; Rivoire M; Droz JP
Nat Clin Pract Urol; 2008 May; 5(5):262-76. PubMed ID: 18398406
[TBL] [Abstract][Full Text] [Related]
9. Management of clinical stage I nonseminomatous germ cell testicular cancer.
Choueiri TK; Stephenson AJ; Gilligan T; Klein EA
Urol Clin North Am; 2007 May; 34(2):137-48; abstract viii. PubMed ID: 17484919
[TBL] [Abstract][Full Text] [Related]
10. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Marwaha S; Venner PM; North SA
Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for good-risk germ cell tumors: current concepts and controversies.
Vaughn DJ
Urol Clin North Am; 2007 May; 34(2):171-7; abstract viii-ix. PubMed ID: 17484922
[TBL] [Abstract][Full Text] [Related]
12. Management of recurrent testicular germ cell tumors.
Sonpavde G; Hutson TE; Roth BJ
Oncologist; 2007 Jan; 12(1):51-61. PubMed ID: 17227900
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy for metastatic germ cell tumours of the testis].
Culine S
Rev Prat; 2007 Feb; 57(4):385-8. PubMed ID: 17455740
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
15. Management of good risk germ-cell tumours.
Troost MM; Sternberg CN; de Wit R
BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of germ cell tumors. Model for interdisciplinary treatment approach].
Schmoll HJ
Med Klin (Munich); 1996 Apr; 91 Suppl 3():80-4. PubMed ID: 8692125
[No Abstract] [Full Text] [Related]
17. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer.
de Haas EC; Zwart N; Meijer C; Nuver J; Boezen HM; Suurmeijer AJ; Hoekstra HJ; van der Steege G; Sleijfer DT; Gietema JA
J Clin Oncol; 2008 Apr; 26(11):1817-23. PubMed ID: 18398146
[TBL] [Abstract][Full Text] [Related]
18. Does age affect the prognosis of patients with testicular germ cell tumor?
Inci K; Dogan HS; Akdogan B; Ergen A; Tasar C; Ozen H
Urol Int; 2007; 79(2):117-23. PubMed ID: 17851279
[TBL] [Abstract][Full Text] [Related]
19. [High-dose chemotherapy with transplantation of autologous stem cells in advanced germ-cell poor-risk testicular tumors].
May M; Georgieva G; Gunia S; Peter N; Steinhauer HB; Hoschke B
Urologiia; 2007; (2):58-63. PubMed ID: 17578200
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome.
Ong TA; Winkler MH; Savage PM; Seckl MJ; Christmas TJ
BJU Int; 2008 Jul; 102(2):198-202. PubMed ID: 18294302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
